Skip to main content
OpenTrials
Completed

NCT Number: NCT03044834

Review of the Paediatric Pleuropulmonary Blastoma French Series

Pleuropulmonary blastoma is a rare embryonic malignant tumour that remains the most frequent malignant tumour of the lung in childhood. The International Pleuro pulmonary Blastoma Registry (IPPB) found only 220 cases in 2009 and 350 in 2015. In France, 20 cases were identified in 2009.

Three histologies are described: type 1 purely cystic, type 2 combined and type 3 solid. Median age at diagnostic is 12 months, 35 months and 41 months respectively. Evolution is possible from type 1 to type 2 or 3 in 10% of the cases.

Since 2009, DICER 1 mutations research is proposed systematically to all families.

PPB symptoms are usually non-specific. Diagnostic is evoked when imaging work up shows bubbles or solid lesions, and confirmed by pathological analysis. However the diagnosis can be difficult because of the proximity with congenital cystic adenomatoid malformation.

The French society of paediatric oncology recommends surgery at first instance. PPB type 1 remains a problem because some are still misdiagnosed as CCAM, a benign lesion. Chemotherapy depends on the PPB type and the quality of the resection. There is a real interest to analyse the French series.

The prognosis of type 2 and 3 is low with a 5 years survival rate of 45-60%, whereas type 1 survival rate is 91%. The French experience reports a 100% survival rate in type 1 and 48% in type 2 and 3. Other prognostic factors are initial size of the tumour, extra pulmonary invasion and quality of surgery.

Early local relapses are possible and late ones concern more often type 2 and 3 with more cerebral metastasis.

In 2009, the french cases were collected, but no update has been performed since. The aim of this retrospective review of the cases since 2000, is to audit the care of PPB patients in France and update the French rare tumour database.

Evoking PPB diagnosis is difficult when imaging shows a neonatal cystic lesion. There are no radiologic criteria in the literature that differentiate congenital pulmonary cystic lesion and PPB type 1. Radiological presentation is however overlapping. Another aim of this study will be to look for a predictive sign of type 1 PPB.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Angers University Hospital, Angers, France

Loading trial locations.

About this study

Multicentre retrospective study

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients born between 01/01/2000 and 01/01/2016 ;
  • Followed up for PPB
  • Treated in a French department of paediatric oncology or paediatric surgery
  • Study agreement

Exclusion criteria

  • Part of the care out of France
  • Study disagreement

Treatment and study plan

PPB

Other

Global current care

Primary outcomes

  1. Overall survival

    Time frame: Within 5 years from the diagnosis

  2. Progression free survival

    Time frame: Within 5 years from the diagnosis

    Characterize the evolution and the global care of PPB in the French series

Secondary outcomes

  1. State of PPB surgical care

    Time frame: Within 5 years from the diagnosis

  2. Radiology sign

    Time frame: Within 5 years from the diagnosis

    Identification of a type 1 PPB predictive radiological sign

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: PPB

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Feb 7, 2017
Registry last updated
Aug 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.